189 related articles for article (PubMed ID: 22849360)
1. Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.
Zhu Z; Shi M; Hu W; Estrella H; Engebretsen J; Nichols T; Briere D; Hosea N; Los G; Rejto PA; Fanjul A
BMC Genomics; 2012 Jul; 13():355. PubMed ID: 22849360
[TBL] [Abstract][Full Text] [Related]
2. Discovery of
Chai X; Sun H; Zhou W; Chen C; Shan L; Yang Y; He J; Pang J; Yang L; Wang X; Cui S; Fu Y; Xu X; Xu L; Yao X; Li D; Hou T
J Med Chem; 2022 Feb; 65(3):2507-2521. PubMed ID: 35077161
[TBL] [Abstract][Full Text] [Related]
3. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
Lamb AD; Massie CE; Neal DE
BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
[TBL] [Abstract][Full Text] [Related]
4. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
5. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
6. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
7. Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.
Leach DA; Panagopoulos V; Nash C; Bevan C; Thomson AA; Selth LA; Buchanan G
Mol Cell Endocrinol; 2017 Jan; 439():261-272. PubMed ID: 27634452
[TBL] [Abstract][Full Text] [Related]
8. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
[TBL] [Abstract][Full Text] [Related]
9. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
10. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.
Lin B; Wang J; Hong X; Yan X; Hwang D; Cho JH; Yi D; Utleg AG; Fang X; Schones DE; Zhao K; Omenn GS; Hood L
PLoS One; 2009 Aug; 4(8):e6589. PubMed ID: 19668381
[TBL] [Abstract][Full Text] [Related]
11. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.
Kaikkonen S; Paakinaho V; Sutinen P; Levonen AL; Palvimo JJ
Mol Endocrinol; 2013 Feb; 27(2):212-23. PubMed ID: 23192983
[TBL] [Abstract][Full Text] [Related]
13. miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.
Pasqualini L; Bu H; Puhr M; Narisu N; Rainer J; Schlick B; Schäfer G; Angelova M; Trajanoski Z; Börno ST; Schweiger MR; Fuchsberger C; Klocker H
Mol Endocrinol; 2015 Jul; 29(7):1037-54. PubMed ID: 26052614
[TBL] [Abstract][Full Text] [Related]
14. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
15. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
18. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
19. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
[TBL] [Abstract][Full Text] [Related]
20. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens.
Jin C; Yang L; Xie M; Lin C; Merkurjev D; Yang JC; Tanasa B; Oh S; Zhang J; Ohgi KA; Zhou H; Li W; Evans CP; Ding S; Rosenfeld MG
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9235-40. PubMed ID: 24928520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
